Development and validation of a predictive model of aromatase inhibitor-induced arthralgia among patients with early breast cancer

Clicks: 1
ID: 325622
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal

Ranked #332 of 333 articles by views in JNCI Journal of the National Cancer Institute

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 333 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
BACKGROUND: Aromatase inhibitor-induced arthralgia (AIA) is common in early-stage breast cancer patients on aromatase inhibitors (AI), potentially compromising adherence and outcomes. We developed and validated prediction models for short- and longer-term AIA. METHODS: Postmenopausal patients with stage I-III breast cancer on adjuvant AI in CANTO (NCT01993498) were included. Primary outcome was AIA (any grade articular/muscular pain, Common Terminology Criteria for Adverse Events [CTCAE] v4.0) at year 1 (Y-1) and 4 (Y-4) cohort visits. Baseline clinical, behavioral, treatment-related, patient-reported (EORTC QLQ-C30, HADS) variables were modeled using multivariable logistic regression and bootstrap in development and temporal validation cohorts. Baseline inflammatory markers were examined in a sub-cohort. RESULTS: The Y-1 and Y-4 development cohorts included 3,065 and 2,390 patients (mean age 64.0 [SD 7.2] and 63.7 years [6.9]), respectively. AIA occurred in 61.3% (Y-1) and 66.1% (Y-4) patients. Validation cohorts included 1,313 (Y-1) and 1,009 (Y-4) patients with similar characteristics. Across models, higher BMI, greater baseline fatigue, prior articular/muscular disease, chemotherapy exposure, pre-existing pain were associated with subsequent AIA; anastrozole use was associated with AIA at Y-4. AUC was 0.62-0.65 in development cohorts; 0.61-0.67 in validation cohorts. In the biomarker sub-cohort (n = 637), higher baseline IL-8 was associated with lower Y-1 AIA odds (OR 0.74, 95% CI 0.56-0.98). CONCLUSION: Using baseline clinical and patient-reported data, we generated models identifying patients at increased risk of early and persistent AIA. While performance was modest, risk stratification could help trigger stepped-care pathways to optimize AI adherence and outcomes. IL-8 association requires independent replication.
Reference Key
openalex_W7203757347 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Pietro Lapidari, Maryam Lustberg, Julie Havas, Martina Pagliuca, Chayma Bousrih, Christelle Jouannaud, Marion Fournier, William Jacot, Laurence Vanlemmens, Kaderbhai Courèche, Anne Kieffer, Baptiste Sauterey, Olivier Tredan, Christelle Lévy, Anne-Laure Martin, Catherine Gaudin, Gwenn Menvielle, Maria Alice Franzoi, Ines Vaz-Luis, Antonio Di Meglio
Journal JNCI Journal of the National Cancer Institute
Year 2026
DOI
10.1093/jnci/djag280
URL
https://doi.org/10.1093/jnci/djag280
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.